Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors.

Trial Profile

Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Rigosertib (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 23 Sep 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 23 Sep 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 23 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top